ArticleThe Journal of investigative dermatology2016
Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.
Article in The Journal of investigative dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Observational
- Type I interferon signaling promotes mucosal inflammation in murine models of colitis.bioRxiv : the preprint server for biology · 2026Article
- Traditional medicine meets modern science: Halofuginone's role in combating autoimmune diseases.Journal of natural medicines · 2025Review
- Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.CPT: pharmacometrics & systems pharmacology · 2025Article
- The Central Roles of Keratinocytes in Coordinating Skin Immunity.The Journal of investigative dermatology · 2024Review
- Article
- Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.Biomedicines · 2022Review
- OTULIN maintains skin homeostasis by controlling keratinocyte death and stem cell identity.Nature communications · 2021Article
- Review
- Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.Therapeutic advances in neurological disorders · 2021Review
- The influence of interferon on healthy and diseased skin.Cytokine · 2020Review
- Article
- The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.Frontiers in immunology · 2020Review
- Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis.Frontiers in immunology · 2019Review
- Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer.Frontiers in pharmacology · 2019Review
- A requirement for slc15a4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice.Scientific reports · 2018Article
- Article
- A clinical review of phototherapy for psoriasis.Lasers in medical science · 2018Review
- Signs of innate immune activation and premature immunosenescence in psoriasis patients.Scientific reports · 2017Article
- The molecular basis for differential type I interferon signaling.The Journal of biological chemistry · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Phototherapy with UV light is a standard treatment for psoriasis, yet the mechanisms underlying the therapeutic effects are not well understood. Studies in human and mouse keratinocytes and in the skin tissues from human patients and mice showed that UV treatment triggers ubiquitination and downregulation of the type I IFN receptor chain IFNAR1, leading to suppression of IFN signaling and an ensuing decrease in the expression of inflammatory cytokines and chemokines. The severity of imiquimod-induced psoriasiform inflammation was greatly exacerbated in skin of mice deficient in IFNAR1 ubiquitination (Ifnar1(SA)). Furthermore, these mice did not benefit from UV phototherapy. Pharmacologic induction of IFNAR1 ubiquitination and degradation by an antiprotozoal agent halofuginone also relieved psoriasiform inflammation in wild-type but not in Ifnar1(SA) mice. These data identify downregulation of IFNAR1 by UV as a major mechanism of the UV therapeutic effects against the psoriatic inflammation and provide a proof of principle for future development of agents capable of inducing IFNAR1 ubiquitination and downregulation for the treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.